Prevalence and risk factors of thyroid nodules in breast cancer women with different clinicopathological characteristics: a cross-sectional study

Chen-yu Ma, Xin-yu Liang, Liang Ran, Lei Hu, Fan-ling Zeng, Rui-ling She, Jun-han Feng, Zhi-yu Jiang, Zhao-xing Li, Xiu-quan Qu, Bai-qing Peng, Kai-nan Wu, Ling-quan Kong
{"title":"Prevalence and risk factors of thyroid nodules in breast cancer women with different clinicopathological characteristics: a cross-sectional study","authors":"Chen-yu Ma, Xin-yu Liang, Liang Ran, Lei Hu, Fan-ling Zeng, Rui-ling She, Jun-han Feng, Zhi-yu Jiang, Zhao-xing Li, Xiu-quan Qu, Bai-qing Peng, Kai-nan Wu, Ling-quan Kong","doi":"10.1007/s12094-024-03488-3","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Association between breast cancer (BC) and thyroid nodules (TNs) is still unclear. This research was to estimate the prevalence and risk factors of TN in Chinese BC women at initial diagnosis.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>1731 Chinese early-stage BC women at initial diagnosis underwent thyroid ultrasound and 1:1 age-matched Chinese healthy women underwent health examination in corresponding period were enrolled for analysis.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Prevalence of TN and TI-RADS ≥ 4 TN in BC patients (56.27% and 9.76%) were higher than healthy people (46.04% and 5.49%), respectively, <i>P</i> &lt; 0.001. Among BC patients, prevalence of TN and TI-RADS ≥ 4 TN in hormone receptor (HR)-positive patients (59.57% and 11.81%) were higher than HR-negative patients (48.77% and 5.10%), respectively, <i>P</i> &lt; 0.001, while without difference between HR-negative patients and healthy people. After adjusting for age and BMI, HR-positive patients had higher risk of TN (OR = 1.546, 95%CI 1.251–1.910, <i>P</i> &lt; 0.001) and TI-RADS ≥ 4 TN (OR = 3.024, 95%CI 1.943–4.708, <i>P</i> &lt; 0.001) than HR-negative patients. Furthermore, the risk of TI-RADS ≥ 4 TN was higher in patients with estrogen receptor (ER) positive (OR = 2.933, 95%CI 1.902–4.524), progesterone receptor (PR) positive (OR = 1.973, 95%CI 1.378–2.826), Ki-67 &lt; 20% (OR = 1.797, 95%CI 1.280–2.522), and tumor size &lt; 2 cm (OR = 1.804, 95%CI 1.276–2.552), respectively, <i>P</i> &lt; 0.001.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Prevalence of TN, especially TI-RADS ≥ 4 TN, in Chinese early-stage BC women was higher than healthy people. HR-positive patients had higher prevalence and risk of TN, while without difference between HR-negative patients and healthy people. The increased risk of TN was correlated with ER-positive, PR-positive, lower Ki-67 expression, and smaller tumor size.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"25 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12094-024-03488-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Association between breast cancer (BC) and thyroid nodules (TNs) is still unclear. This research was to estimate the prevalence and risk factors of TN in Chinese BC women at initial diagnosis.

Methods

1731 Chinese early-stage BC women at initial diagnosis underwent thyroid ultrasound and 1:1 age-matched Chinese healthy women underwent health examination in corresponding period were enrolled for analysis.

Results

Prevalence of TN and TI-RADS ≥ 4 TN in BC patients (56.27% and 9.76%) were higher than healthy people (46.04% and 5.49%), respectively, P < 0.001. Among BC patients, prevalence of TN and TI-RADS ≥ 4 TN in hormone receptor (HR)-positive patients (59.57% and 11.81%) were higher than HR-negative patients (48.77% and 5.10%), respectively, P < 0.001, while without difference between HR-negative patients and healthy people. After adjusting for age and BMI, HR-positive patients had higher risk of TN (OR = 1.546, 95%CI 1.251–1.910, P < 0.001) and TI-RADS ≥ 4 TN (OR = 3.024, 95%CI 1.943–4.708, P < 0.001) than HR-negative patients. Furthermore, the risk of TI-RADS ≥ 4 TN was higher in patients with estrogen receptor (ER) positive (OR = 2.933, 95%CI 1.902–4.524), progesterone receptor (PR) positive (OR = 1.973, 95%CI 1.378–2.826), Ki-67 < 20% (OR = 1.797, 95%CI 1.280–2.522), and tumor size < 2 cm (OR = 1.804, 95%CI 1.276–2.552), respectively, P < 0.001.

Conclusions

Prevalence of TN, especially TI-RADS ≥ 4 TN, in Chinese early-stage BC women was higher than healthy people. HR-positive patients had higher prevalence and risk of TN, while without difference between HR-negative patients and healthy people. The increased risk of TN was correlated with ER-positive, PR-positive, lower Ki-67 expression, and smaller tumor size.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
具有不同临床病理特征的乳腺癌妇女甲状腺结节的患病率和风险因素:一项横断面研究
背景乳腺癌(BC)与甲状腺结节(TNs)之间的关系尚不清楚。方法1731名初诊的中国早期BC女性接受甲状腺超声检查,并与1:1年龄匹配的中国健康女性接受同期健康检查进行分析。结果BC患者TN和TI-RADS≥4 TN的患病率(56.27%和9.76%)分别高于健康人群(46.04%和5.49%),P < 0.001。在 BC 患者中,激素受体(HR)阳性患者 TN 和 TI-RADS ≥ 4 TN 的发生率(59.57% 和 11.81%)分别高于 HR 阴性患者(48.77% 和 5.10%),P< 0.001,而 HR 阴性患者与健康人之间无差异。调整年龄和体重指数后,HR 阳性患者比 HR 阴性患者有更高的 TN 风险(OR = 1.546,95%CI 1.251-1.910,P < 0.001)和 TI-RADS ≥ 4 TN 风险(OR = 3.024,95%CI 1.943-4.708,P < 0.001)。此外,雌激素受体(ER)阳性(OR = 2.933,95%CI 1.902-4.524)、孕激素受体(PR)阳性(OR = 1.973,95%CI 1.378-2.826)、Ki-67 < 20% (OR = 1.797,95%CI 1.280-2.522),肿瘤大小< 2 cm(OR = 1.804,95%CI 1.276-2.552),P< 0.001.结论中国早期BC女性TN,尤其是TI-RADS≥4 TN的患病率高于健康人群。HR阳性患者的TN患病率和患病风险均较高,而HR阴性患者与健康人之间无差异。TN风险的增加与ER阳性、PR阳性、较低的Ki-67表达和较小的肿瘤大小相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
lncSNHG16 promotes hepatocellular carcinoma development by inhibiting autophagy Efficacy and safety of camrelizumab combined with chemotherapy in the treatment of advanced biliary malignancy and associations between peripheral blood lymphocyte subsets and clinical outcomes Emerging immunologic approaches as cancer anti-angiogenic therapies Safety profile of trastuzumab originator vs biosimilars: a systematic review and meta-analysis of randomized clinical trials Construction and clinical significance of prognostic risk markers based on cancer driver genes in lung adenocarcinoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1